A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

Exclusion Criteria

• •Prior exposure to agents directed at human epidermal growth factor receptor (HER) axis (e.g. erlotinib, gefitinib, cetuximab)
• •Participants whose tumors harbor an EGFR-activating mutation
• •Prior chemotherapy or therapy with systemic anti-neoplastic therapy for advanced disease before Screening
• •Use of pemetrexed in maintenance setting (pemetrexed allowed during the chemotherapy run-in)
• •Participants who have undergone complete tumor resection after responding to the platinum-based chemotherapy during the Screening phase
• •Any other malignancies within 5 years, except for curatively resected carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal carcinoma in situ, or organ-confined prostate cancer
• •Central nervous system (CNS) metastases or spinal cord compression that has not been definitely treated with surgery and/or radiation, or treated CNS metastases or spinal cord compression without stable disease for ≥2 months
• •Human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
• •Any inflammatory changes of the surface of the eye